As investors well know, biotechnology companies are notorious for over-promising and under-delivering. However, if you invest at the right time in a promising biotech company that’s undervalued and on the verge of a product breakthrough –- well, the profits can be astronomical. This issue, we explore just such an opportunity: Oncothyreon, a therapeutic drug development company with activities centered in the field of cancer treatment. The company seeks to bring to market groundbreaking cancer vaccines to induce the immune system to attack cancer cells. This innovative biotech company has designed a drug that’s been acing its clinical trials, with FDA approval perhaps only months away. Here’s the kicker: the stock is still cheap, relative to its prospects. To find out more, read on!
